BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X, Chen Y. Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies. Front Oncol 2021;11:680834. [PMID: 34123850 DOI: 10.3389/fonc.2021.680834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ishikawa T, Ogura Y, Tanaka K, Nagashima H, Sasayama T, Endo M, Minami Y. Ror1 is expressed inducibly by Notch and hypoxia signaling and regulates stem cell-like property of glioblastoma cells. Cancer Sci 2023;114:561-73. [PMID: 36314076 DOI: 10.1111/cas.15630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hassannia H, Amiri MM, Ghaedi M, Sharifian RA, Golsaz-Shirazi F, Jeddi-Tehrani M, Shokri F. Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model. Cancers (Basel) 2022;14. [PMID: 36497309 DOI: 10.3390/cancers14235827] [Reference Citation Analysis]
3 Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, Mobarak H, Ahmadi A, Hamblin MR, Aref AR. Receptor Tyrosine Kinase Inhibitors in Cancer Immunotherapy.. [DOI: 10.21203/rs.3.rs-2251865/v1] [Reference Citation Analysis]
4 Ghaderi A, Zhong W, Okhovat MA, Aschan J, Svensson A, Sander B, Schultz J, Olin T, Österborg A, Hojjat-farsangi M, Mellstedt H. A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. Pharmaceutics 2022;14:2238. [DOI: 10.3390/pharmaceutics14102238] [Reference Citation Analysis]
5 John M, Ford CE. Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1. Biomedicines 2022;10:2559. [PMID: 36289823 DOI: 10.3390/biomedicines10102559] [Reference Citation Analysis]
6 Mouhssine S, Gaidano G. Richter Syndrome: From Molecular Pathogenesis to Druggable Targets. Cancers 2022;14:4644. [DOI: 10.3390/cancers14194644] [Reference Citation Analysis]
7 Zhang D, He C, Guo Y, Li J, Li B, Zhao Y, Yu L, Chang Z, Pei H, Yang M, Li N, Zhang Q, He Y, Pan Y, Zhao ZJ, Zhang C, Chen Y. Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. BMC Med 2022;20:257. [PMID: 35999600 DOI: 10.1186/s12916-022-02465-3] [Reference Citation Analysis]
8 Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, Rader C. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 2022;41:4104-14. [PMID: 35859167 DOI: 10.1038/s41388-022-02416-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nadanaka S, Tamura JI, Kitagawa H. Chondroitin Sulfates Control Invasiveness of the Basal-Like Breast Cancer Cell Line MDA-MB-231 Through ROR1. Front Oncol 2022;12:914838. [PMID: 35712490 DOI: 10.3389/fonc.2022.914838] [Reference Citation Analysis]
10 Yan Q, Fang X, Li C, Lan P, Guan X. Oncofetal proteins and cancer stem cells. Essays in Biochemistry 2022. [DOI: 10.1042/ebc20220025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape. Expert Opin Ther Targets 2022. [PMID: 35574694 DOI: 10.1080/14728222.2022.2077188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chocarro L, Arasanz H, Fernández-rubio L, Blanco E, Echaide M, Bocanegra A, Teijeira L, Garnica M, Morilla I, Martínez-aguillo M, Piñeiro-hermida S, Ramos P, Lasarte JJ, Vera R, Kochan G, Escors D. CAR-T Cells for the Treatment of Lung Cancer. Life 2022;12:561. [DOI: 10.3390/life12040561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Guo Y, Pei H, Lu B, Zhang D, Zhao Y, Wu F, Sun H, Huang J, Li P, Yi C, Zhu C, Pan Y, Wu S, Chen C, Xu X, Chen Y. Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia. Cell Death Discov 2022;8:82. [PMID: 35210425 DOI: 10.1038/s41420-022-00884-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 John M, Ford C. Pan-tissue and -cancer analysis of ROR1 and ROR2 transcript variants identify novel functional significance for an alternative splice variant of ROR1.. [DOI: 10.1101/2021.11.24.469652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther 2021;4:222-7. [PMID: 34805745 DOI: 10.1093/abt/tbab023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, Illescas E, Quezada MJ, Lopez-Bergami P. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation. J Biomed Sci 2021;28:76. [PMID: 34774050 DOI: 10.1186/s12929-021-00776-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]